Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASTURE: Spartalizumab in Unresectable Stage III NSCLC
NCT03945227Phase 2Withdrawn
- Sponsor
- Yonsei University
- Start
- Jun 2019
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Planned start Jun 2019; status: withdrawn.
02
Drugs
spartalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03945227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945227.